Gut-liver Axis
7th Aug, 2019

This post is specifically for health practitioners. Create a free account

Alternatively, view general public info.

Learn more about vital.ly

GLA Essentials

The gut microbiota consists of a diverse community of bacterial species in the gastrointestinal (GI) tract which exists symbiotically with the human host. A healthy and stable gut microbiota community plays a vital role in maintaining motility, permeability, secretion and immunity of the gut. The liver is intimately linked to the gut via the portal vein. A healthy or diseased liver may be impacted by exposure to gut microbiota and their metabolites translocating across the gut lumen (1).

There is a wealth of data linking conditions such as non-alcoholic fatty liver disease (NAFLD), alcohol-related liver disease (ALD), primary sclerosing cholangitis (PSC) and cirrhosis with reduced bacterial diversity and gut dysbiosis (1,2).

Table 1. Liver disease definitions

Gut-liver axis Essentials Table 1

The relationship between the gut microbiota and liver diseases is complex. Gut dysbiosis and the translocation of microbes and/or microbial metabolites across the intestinal epithelium into the mesenteric lymph nodes and liver may influence the degree of hepatic steatosis, inflammation and fibrosis through multiple interactions with the host’s immune system and other cell types including nonparenchymal and parenchymal liver cells. Increased hepatic steatosis, fibrosis and portal hypertension, in turn, exacerbate intestinal permeability resulting in further bacterial translocation (2,3,4).

The liver receives 70% of its blood supply through the portal vein and provides the first-pass metabolism for the GI luminal contents, which include dietary nutrients, toxins and xenobiotics  as well as the gut microbiota and microbial metabolites that translocate across the intestinal epithelium (2). In turn, the liver secretes bile acids which modify the intestinal microbiome and act as signalling molecules between the liver, the gut microbiota and the intestine (5).

Recent studies have highlighted the causal role of the gut microbiota in the development of liver diseases and the use of probiotics or prebiotics to modulate the gut microbiota improves some parameters associated with liver disease, suggesting a potential preventive or therapeutic strategy for these diseases (1,6).

 

Figure 1. Pathogenesis of NASH - The “Multiple Hit Theory”. Adapted from (7CC BY-NC-ND 4.0

The gut microbiota, oxidative stress, and mitochondrial damage play key roles in the pathogenesis of NASH. Inflammation precedes steatosis in environmentally and genetically predisposed subjects. Numerous insults act together to induce NAFLD, including insulin resistance, hormones secreted from the adipose tissue, nutritional factors, endotoxins (lipopolysaccharide) released by the gut microbiota, oxidative stress damage, and genetic and epigenetic factors. These insults act on liver parenchymal cells via toll-like receptors to drive the progression of NASH.

Gut-liver axis Essentials Fig 1

 

 

Traditional Understanding

It has long been recognised that microbial translocation releases bacterial products that play a key role in the progression of chronic liver disease by promoting hepatic injury and inflammation. It is only fairly recently however, that we are beginning to understand the circumstances under which gut permeability occurs and to discover bacterial metabolites that promote liver disease (8).

 

Latest Research

Non-alcoholic fatty liver disease (NAFLD)/Non-alcoholic steatohepatitis (NASH)

Studies show that the intestinal microbiota and dysbiosis play an important role in the pathogenesis and severity of NAFLD/NASH.

Figure 2. Importance of balanced gut microbiota and the consequences of gut dysbiosis. Adapted from (7CC BY-NC-ND 4.0

Gut-liver axis Essentials Fig 1

 

  • Altered microbiome composition and diversity are demonstrated in individuals with NAFLD/NASH, however, no consistent causative microbiota signature has been identified. Evidence indicates that individuals with NASH have a high prevalence (50% – 78%) of small intestinal bacterial overgrowth (SIBO) (2,6,9,10)
  • Increase in intestinal permeability is five times more likely to occur in individuals with NAFLD compared with healthy individuals (11)
  • NAFLD and NASH are commonly associated with obesity and other components of the metabolic syndrome which are linked to the changes in the intestinal microbiome. Changes in the composition of the intestinal microbiome associated with carbohydrate, lipid and protein metabolism predict NAFLD severity (12)
  • Bifidobacteria appear to have a protective role against the development of NAFLD and obesity, highlighting their possible use in treatment and prevention (13)
  • Immunomodulatory bacterial metabolites play an important role in NAFLD (14)

 

Figure 3. Effect of gut microbiome in NAFLD development and progression to NASH. Adapted from (15CC BY-NC-ND 4.0

Gut-liver axis Essentials Fig 3

 

Alcoholic liver disease (ALD)

The spectrum of ALD ranges from simple alcoholic steatosis to steatohepatitis, eventually progressing to fibrosis and cirrhosis. The gut microbiota changes both quantitatively and qualitatively in the setting of ALD, with the development of SIBO and dysbiosis (2).

  • Individual susceptibility to ALD is substantially driven by the gut microbiome and there is strong evidence for a causal role of the microbiome in ALD (6,16)
  • Disruption of the gut barrier is a prerequisite for ALD, resulting in bacterial translocation. Alcohol consumption disrupts the gut barrier, increases gut permeability and induces bacterial translocation both in ALD patients and in experimental models with ALD. Alcohol consumption also causes dysbiosis with changes in both the quantity and ratios of microbiome populations (17)
  • Research suggests that the control of bacterial overgrowth and adherent bacterial content is essential to the protective mechanisms against alcohol-induced liver toxicity (6,18)
  • Metabolites produced by the gut microbiome are involved not only in cell dysfunction and liver disease but also in the psychological symptoms of alcohol dependence (19)

 

Advanced liver disease

Fibrosis, cirrhosis, hepatocellular carcinoma (HCC), primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are all associated with gut microbiome changes, including dysbiosis and gut permeability (20).

The gut microbiota is critically important in the development of hepatic fibrogenesis. The composition and function of the gut microbiota are altered in patients with fibrosis (21). Increased circulating lipopolysaccharide (LPS) levels lead to a chronic inflammatory state leading to the development of hepatic fibrosis and eventually cirrhosis (2).

  • Profound changes in the microbiota occur with the development of liver cirrhosis and individuals with cirrhosis have distinct faecal microbial communities relative to healthy individuals, with an overall decrease in microbiome diversity (2,6). Dysbiosis, SIBO and increased gut permeability allow bacterial translocation and uptake of endotoxins, inducing hepatic and systemic inflammation (1)
  • Many bacteria enriched in the gut microbiota of cirrhotic patients appear to be of oral origin, suggesting an invasion of the lower intestinal tract by the oral microbiome (22)
  • Bacterial translocation seems to play an important role as the trigger in cirrhosis, while complications of liver cirrhosis are mainly due to portal hypertension (PHT). Systemic pro-inflammatory states might persist after efficient treatment of PHT, fuelling immune dysregulation and further triggering the development of acute-on-chronic liver failure (ACLF). Microbiome and inflammation directed treatments are emerging as promising targets in ACLF (4)
  • Results from a Cochrane review indicate that lactulose reduces complications of cirrhosis such as liver failure, hepatorenal syndrome, variceal bleeding and overall mortality (23)
  • Evidence suggests that the gut microbiome could be involved in the initiation and progression of HCC via alterations in bile acid metabolism and release of inflammatory cytokines (6,9)
Loading...
References
1Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018 Jan;47(2):192–202.
2Shen T-CD, Pyrsopoulos N, Rustgi VK. Microbiota and the liver. Liver Transpl. 2018;24(4):539–50.
3Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65(12):2035–44.
4Trebicka J, Reiberger T, Laleman W. Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure. Visc Med. 2018 Aug;34(4):270–5.
5Ridlon JM, Kang D-J, Hylemon PB, Bajaj JS. Gut microbiota, cirrhosis and alcohol regulate bile acid metabolism in the gut. Dig Dis. 2015;33(3):338–45.
6Cassard A-M, Gérard P, Perlemuter G. Microbiota, Liver Diseases, and Alcohol. Microbiol Spectr. 2017;5(4).
7Borrelli A, Bonelli P, Tuccillo FM, Goldfine ID, Evans JL, Buonaguro FM, et al. Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches. Redox Biol. 2018;15:467–79.
8Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013 May;29(3):264–70.
9Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res. 2018 Mar;2(1):43–51.
10de Faria Ghetti F, Oliveira DG, de Oliveira JM, de Castro Ferreira LEVV, Cesar DE, Moreira APB. Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis. Eur J Nutr. 2018 Apr;57(3):861–76.
11Bluemel S, Williams B, Knight R, Schnabl B. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016 01;311(6):G1018–36.
12Puri P, Sanyal AJ. The Intestinal Microbiome in Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease. 2018 Feb;22(1):121–32.
13Nobili V, Putignani L, Mosca A, Chierico FD, Vernocchi P, Alisi A, et al. Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players? Arch Med Sci. 2018 Jan;14(1):81–7.
14Rau M, Rehman A, Dittrich M, Groen AK, Hermanns HM, Seyfried F, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J. 2018 Dec;6(10):1496–507.
15Bashiardes S, Shapiro H, Rozin S, Shibolet O, Elinav E. Non-alcoholic fatty liver and the gut microbiota. Mol Metab. 2016 Sep;5(9):782–94.
16Llopis M, Cassard AM, Wrzosek L, Boschat L, Bruneau A, Ferrere G, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016 May;65(5):830–9.
17Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res. 2017 Dec;1(4):197–207.
18Dubinkina VB, Tyakht AV, Odintsova VY, Yarygin KS, Kovarsky BA, Pavlenko AV, et al. Links of gut microbiota composition with alcohol dependence syndrome and alcoholic liver disease. Microbiome. 2017 17;5(1):141.
19Leclercq S, de Timary P, Delzenne NM, Stärkel P. The link between inflammation, bugs, the intestine and the brain in alcohol dependence. Transl Psychiatry. 2017 Feb;7(2):e1048.
20Davis BC, Bajaj JS. The Human Gut Microbiome in Liver Diseases. Semin Liver Dis. 2017 May;37(2):128–40.
21Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764–75.
22Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014 Sep;513(7516):59–64.
23Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044.